Evotec SE Reports Q1 2025 Financial Results Amid Soft Market

Evotec SE, headquartered in Hamburg, Germany, reported a decrease in Q1 2025 group revenues by 4% to €200 million, a reflection of the challenging drug discovery market. Despite this, Just – Evotec Biologics, a branch of Evotec, showed continued revenue growth, jumping by 11% compared to the previous year. The company remains committed to its strategy focused on high-growth segments and operational efficiency.

The quarter witnessed strong advances in Evotec’s strategic partnership with Bristol Myers Squibb, specifically in protein degradation, which brought in milestone payments totaling $75 million. Additionally, Evotec received a grant from the Korean government to support the development of antibody treatments for lung diseases.

For 2025, Evotec anticipates group revenues between €840 million and €880 million, with plans to accelerate growth relative to 2024. Its long-term outlook for 2028 includes a targeted compound annual growth rate of 8-12% in group revenues and an anticipated EBITDA margin above 20%.